Holroyd KB - Search Results

1

Framingham risk score based vascular outcomes in acute versus chronic HIV cohorts after 6 years of ART.

Holroyd KB, Han WM, Apornpong T, Trautmann L, Gatechompol S, Hiransuthikul A, Ubolyam S, Sacdalan C, Sriplienchan S, Kanaprach R, Kerr S, Avihingsanon A, Spudich S, Chan P. Holroyd KB, et al. HIV Med. 2024 Feb 21. doi: 10.1111/hiv.13621. Online ahead of print. HIV Med. 2024. PMID: 38383057

2

Metabolic and Toxic Myelopathies.

Holroyd KB, Berkowitz AL. Holroyd KB, et al. Continuum (Minneap Minn). 2024 Feb 1;30(1):199-223. doi: 10.1212/CON.0000000000001376. Continuum (Minneap Minn). 2024. PMID: 38330479 Review.

3

Impact of steatotic liver disease and non-alcoholic steatohepatitis on cognitive impairment in people living with HIV: A cross-sectional study.

Han WM, Hiransuthikul A, Holroyd KB, Apornpong T, Lwin HM, Gatechompol S, Ubolyam S, Kerr S, Avihingsanon A; HIV-NAT 006 study team and 207 study team. Han WM, et al. Among authors: holroyd kb. HIV Med. 2023 Dec;24(12):1233-1243. doi: 10.1111/hiv.13579. Epub 2023 Nov 17. HIV Med. 2023. PMID: 37975283

4

Central Nervous System Neuroimmunologic Complications of COVID-19.

Holroyd KB, Conway SE. Holroyd KB, et al. Semin Neurol. 2023 Apr;43(2):229-250. doi: 10.1055/s-0043-1767713. Epub 2023 Apr 20. Semin Neurol. 2023. PMID: 37080234

5

Historical Perspectives on the Neurologic Manifestations of Viral Pandemics.

Holroyd KB, Berkowitz AL. Holroyd KB, et al. Semin Neurol. 2023 Apr;43(2):187-194. doi: 10.1055/s-0043-1767714. Epub 2023 Apr 10. Semin Neurol. 2023. PMID: 37037211

6

Quantifying the economic burden to patients of relapse events from neuromyelitis optica spectrum disorders: A cross-sectional survey.

Rice DR, Holroyd KB, Pua DK, Levy M, Mateen FJ, Bhattacharyya S. Rice DR, et al. Among authors: holroyd kb. Mult Scler Relat Disord. 2023 Mar;71:104580. doi: 10.1016/j.msard.2023.104580. Epub 2023 Feb 15. Mult Scler Relat Disord. 2023. PMID: 36805175

7

Use of Transcranial Doppler as a Biomarker of CAR T Cell-Related Neurotoxicity.

Holroyd KB, Rubin DB, LaRose S, Monk A, Nikiforow S, Jacobson C, Vaitkevicius H. Holroyd KB, et al. Neurol Clin Pract. 2022 Feb;12(1):22-28. doi: 10.1212/CPJ.0000000000001130. Neurol Clin Pract. 2022. PMID: 36157627 Free PMC article.

8

Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors.

Conway SE, Pua DKA, Holroyd KB, Galetta K, Bhattacharyya S. Conway SE, et al. Among authors: holroyd kb. Mult Scler. 2023 Mar;29(3):471-474. doi: 10.1177/13524585221117949. Epub 2022 Aug 11. Mult Scler. 2023. PMID: 35957594

9

Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.

Holroyd KB, Healy BC, Conway S, Houtchens M, Bakshi R, Bhattacharyya S, Bose G, Galetta K, Kaplan T, Severson C, Singhal T, Stazzone L, Zurawski J, Polgar-Turcsanyi M, Saxena S, Paul A, Glanz BI, Weiner HL, Chitnis T. Holroyd KB, et al. Mult Scler Relat Disord. 2022 Nov;67:104079. doi: 10.1016/j.msard.2022.104079. Epub 2022 Jul 28. Mult Scler Relat Disord. 2022. PMID: 35952457 Free PMC article.

10

Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series.

Manzano GS, Holroyd KB, Kaplan T, Bhattacharyya S, Chitnis T, Hotan G, Zurawski J, Galetta KM, Mateen FJ. Manzano GS, et al. Among authors: holroyd kb. Mult Scler Relat Disord. 2022 Jul;63:103861. doi: 10.1016/j.msard.2022.103861. Epub 2022 May 10. Mult Scler Relat Disord. 2022. PMID: 35576727

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page